DRAVP ID  DRAVPe01802

Peptide Name   FBP

Sequence  RGAHIKGRWKSRCHRF

Sequence Length  16

UniProt ID  No entry found

Source  Synthetic construct

Target Organism  Influenza A virus, Influenza B virus, SARS-CoV-2

Assay  Plaque reduction assay

Activity 

• [Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(IC50=3.9 μg/ml);
• influenza A virus(H3N2): inhibition of viral replication in MDCK cells(IC50=1.6 μg/ml);
• influenza B virus: inhibition of viral replication in MDCK cells(IC50=7.1 μg/ml);
• SARS-CoV-2 HKU001a: inhibition of viral replication in Vero E6 cells(IC50=2.9 μg/ml);
• SARS-CoV-2 B.1.1.63: inhibition of viral replication in Vero E6 cells(IC50=3.0 μg/ml);
• SARS-CoV-2 Delta: inhibition of viral replication in Vero E6 cells(IC50=3.9 μg/ml).

Hemolytic Activity 

• [Ref.35259078]No significant haemolysis was observed when Turkey red blood cells (RBC) were treated with FBP.

Cytotoxicity 

• [Ref.35259078]no significant cytotoxicity was detected in MDCK cells treated with 1 mg/ml of FBP.

Binding Target  HA

Mechanism  FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway.the notable antiviral activity and fusion inhibition activity of FBP on SARS-CoV-2 could be attributed to the inhibition of FBP on endosomal acidification

PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L

Literature 1

Title   Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.

Pubmed ID   35259078

Reference   Emerg Microbes Infect. 2022 Dec;11(1):926-937.

Author   Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.

DOI   10.1080/22221751.2022.2051753